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Abstract
Background: The objective of this exploratory analysis was to characterize efficacy and onset of action of a 3-
month treatment period with risperidone long-acting injection (RLAI), adjunctive to an individual’s treatment
regimen, in subjects with symptomatic bipolar disorder who relapsed frequently and had significant symptoms of
mania and/or depression.
Methods: Subjects with bipolar disorder with ≥4 mood episodes in the past 12 months entered the open-label
stabilization phase preceding a placebo-controlled, double-blind study. Subjects with significant depressive or
manic/mixed symptoms at baseline were analyzed. Significant depressive symptoms were defined as Montgomery-
Åsberg Depression Rating Scale (MADRS) ≥16 and Young Mania Rating Scale (YMRS) < 16; manic/mixed symptoms
were YMRS ≥16 with any MADRS score. Subjects received open-label RLAI (25-50 mg every 2 weeks) for 16 weeks,
adjunctive to a subject’s individualized treatment for bipolar disorder (mood stabilizers, antidepressants, and/or
anxiolytics). Clinical status was evaluated with the Clinical Global Impressions of Bipolar Disorder-Severity (CGI-BP-S)
scale and changes on the MADRS and YMRS scales. Within-group changes were evaluated using paired t tests;
categorical differences were assessed using Fisher exact test. No adjustment was made for multiplicity.
Results: 162 subjects who relapsed frequently met criteria for significant mood symptoms at open-label baseline;
59/162 (36.4%) had depressive symptoms, 103/162 (63.6%) had manic/mixed symptoms. Most subjects (89.5%)
were receiving ≥1 medication for bipolar disorder before enrollment. Significant improvements were observed for
the total population on the CGI-BP-S, MADRS, and YMRS scales (p < .001 vs. baseline, all variables). Eighty-two
(53.3%) subjects achieved remission at the week 16 LOCF end point. The subpopulation with depressive symptoms
at open-label baseline experienced significant improvement on the CGI-BP-S and MADRS scales (p < .001 vs.
baseline, all variables). Subjects with manic/mixed symptoms at baseline had significant improvements on the CGI-
BP-S and YMRS scales (p < .001 vs. baseline, all variables). No unexpected tolerability findings were observed.
Conclusions: Exploratory analysis of changes in overall clinical status and depression/mania symptoms in subjects
with symptomatic bipolar disorder who relapse frequently showed improvements in each of these areas after
treatment with RLAI, adjunctive to a subject’s individualized treatment. Prospective controlled studies are needed
to confirm these findings.
Background
Bipolar disorder is a serious, lifelong mental illness asso-
ciated with marked psychosocial disability [1-5].
Although the goal of treatment during an acute episode
is symptom control to preserve psychosocial functioning
[6], patients with bipolar disorder who relapse frequently
are a difficult-to-treat population [7,8]. In many cases,
clinicians may initiate treatment with monotherapy;
however, therapeutic management often requires the
addition of adjunctive medications that can include
mood stabilizers, antidepressants, or antipsychotics [6].
A significant barrier to treatment of bipolar disorder is
nonadherence. In a sample of outpatients, 24% of sub-
jects were found to be at least partially nonadherent on
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associated with poor adherence include history of rapid
cycling, bipolar type I disorder, and greater illness sever-
ity [9,10]. Poor adherence to medication has been asso-
ciated with a higher rate of recurrence and
hospitalization [11,12]. Subjects who were adherent at
least 75% of the time were at lower risk for all-cause
rehospitalization and mental health-related rehospitaliza-
tion [12]. Therefore, improving adherence is likely to
result in improved treatment outcomes.
Oral antipsychotics are often used adjunctively to treat
the symptoms of bipolar disorder, but their effectiveness
may be compromised by poor medication adherence.
Long-acting injectable atypical antipsychotics may allow
clinicians to identify and respond more easily to poor
adherence [13]. One long-term, prospective study of acutely
manic inpatients with bipolar disorder and a history of
poor or partial adherence found that risperidone long-act-
ing injection (RLAI) significantly decreased hospitalization
rates and reduced discontinuation of all medications the
patients were taking [14]. Further, RLAI as maintenance
therapy has been observed to significantly delay time to
relapse in subjects with bipolar disorder when used either
as monotherapy or as an adjunct to individualized pharma-
cotherapy in subjects who relapse frequently [15,16].
The objective of this post hoc analysis was to examine
clinical, symptomatic, and functional outcomes during
the 16-week, open-label phase of an international (Uni-
ted States and India), double-blind, relapse-prevention
s t u d ye x a m i n i n gt h ea d d i t i o no fa d j u n c t i v eR L A It o
individualized pharmacotherapy in subjects with bipolar
disorder who relapsed frequently over the previous 12
months (NCT00094926) [15]. The aim of the analysis
was to determine whether the addition of RLAI to indi-
vidual treatment regimens of mood stabilizers, antide-
pressants, and/or anxiolytics was beneficial in a subset
of subjects from this study who were experiencing
depressive or manic/mixed symptoms.
Methods
Study Design
This post hoc analysis examined data from the 16-week,
open-label stabilization phase that preceded the rando-
mized, double-blind, relapse-prevention phase. The pro-
tocol was approved by an institutional review board or
ethics committee at each site, and the study was con-
ducted in accordance with current International Confer-
ence on Harmonization/World Health Organization
Good Clinical Practice guidelines and the Declaration of
Helsinki.
Subjects
Eligible subjects were 18-70 years of age, had bipolar
type I or II disorder, diagnosed using the Diagnostic and
Statistical Manual of Mental Disorders, Fourth Edition,
Text Revision, and had experienced 4 or more mood
episodes requiring psychiatric intervention in the pre-
vious 12 months [15]. In the original study, subjects
with any degree of mood symptom severity were
included. The current analysis focused only on subjects
with significant depressive or manic/mixed symptoms at
open-label baseline (depressive symptoms: Montgomery-
Åsberg Depression Rating Scale [MADRS] [17] ≥16 and
Young Mania Rating Scale [YMRS] [18] < 16; manic/
mixed symptoms: YMRS ≥16 with any MADRS score).
Treatment
RLAI 25 mg every 2 weeks was initiated at open-label
baseline, with optional dosage increases to 37.5 mg at
week 4 and to 50 mg at week 10 (per the investigators’
clinical judgment). Oral antipsychotics that subjects
were taking before the study were continued for 3
weeks after the first RLAI injection, and subjects who
were not taking oral antipsychotics received oral risperi-
done. Additional medications for bipolar disorder were
individually determined for each subject and could
include any number or combination of antidepressants,
mood stabilizers, and anxiolytics, with the exception of
carbamazepine, oxcarbazepine, fluoxetine, and paroxe-
tine. These medications were initiated, resumed, or
changed at the discretion of the investigators at any
time during the first 12 weeks of open-label
stabilization.
Assessments
Clinical status was determined by the Clinical Global
Impressions of Bipolar Disorder-Severity (CGI-BP-S)
scale [19];manic and depressive symptoms were mea-
sured using the YMRS and MADRS, respectively.
Assessments were performed at baseline and weeks 4, 8,
12, and 16. Remission was defined as YMRS total score
≤8, MADRS total score ≤10, and CGI-BP-S score ≤2.
Functioning was assessed by the Global Assessment of
Functioning (GAF) scale [20], conducted at baseline and
at week 16. Scores on the GAF scale range from 0 to
100, with higher scores indicating better functioning.
Safety was determined by adverse event (AE) monitoring
at each visit.
Statistical Analysis
Efficacy and safety outcomes were analyzed in subjects
enrolled in the open-label phase who received ≥1d o s e
of RLAI. Demographic and baseline characteristics were
summarized using descriptive statistics. Last-observa-
tion-carried-forward (LOCF) methodology was used for
the YMRS, MADRS, CGI-BP-S, and GAF analyses at
end point. Subjects completing 16 weeks of treatment
(completers) also were evaluated. A change of ≥10
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group changes from open-label baseline were evaluated
using paired t tests; categorical differences were assessed
by Fisher exact test. All statistical tests were 2-sided,
a n dt h en o m i n a lt y p eIe r r o rw a sf i x e da t0 . 0 5 .N o
adjustments were made for multiplicity.
Results
Baseline Demographics, Clinical Characteristics, and
Disposition
One hundred sixty-two (58.9%) of the 275 subjects who
enrolled in the original study had significant mood
symptoms at open-label baseline. Of the 162 subjects,
59 (36.4%) subjects had significant depressive symptoms
and 103 (63.6%) had significant manic/mixed symptoms
(Table 1). Of the subjects with current depressive symp-
toms, 81.4% were diagnosed with bipolar type I disor-
der, as were 93.2% of subjects with manic/mixed
symptoms. A higher percentage of symptomatic women
(44.3%) than symptomatic men (30.4%) had significant
depressive symptoms; 69.6% of symptomatic men and
55.7% of symptomatic women had significant manic/
mixed symptoms. The most recent episode for 74.6% of
subjects with significant current depressive symptoms
was a depressive episode; the most recent episode for
70.9% of subjects with significant manic/mixed symp-
toms was a manic episode. Overall, 74.1% of subjects
with significant mood symptoms completed the 16-
week open-label phase: 74.6% subjects with depressive
symptoms and 73.8% with manic/mixed symptoms
(Table 1).
Bipolar Disorder Medication Use and RLAI Dose
Most subjects in the total symptomatic population at
baseline (89.5%) were taking ≥1 medication for bipolar
disorder before enrollment; 47 (29.0%) were receiving
oral antipsychotics. For subjects who completed 16
weeks of treatment, with the exception of a higher use
of antidepressants compared with baseline (42.5 vs.
29.6%), the number of medications taken for bipolar dis-
order was generally similar at baseline and week 16
(Table 2).
Of depressive and manic/mixed subjects, 91.5% and
88.3% at baseline, respectively, were taking ≥1 medica-
tion; similar proportions of subjects were taking antipsy-
chotics. At week 16, with the exception of a higher use
of antidepressants compared with baseline for the
depressive population (63.6% vs. 44.1%), the number of
medications received for bipolar disorder was generally
similar at baseline and week 16.
The median dose of RLAI during the open-label stabi-
lization phase for all symptomatic subjects was 25 mg
every 2 weeks; the mean doses and the dose
distributions for the depressive and manic/mixed groups
were similar (Table 1).
Total Population of Subjects with Significant Mood
Symptoms
Efficacy
The clinical status improved significantly by week 4 and
at each subsequent time point, as determined by CGI-
BP-S total scores (Figure 1). Mood symptoms also
improved, as reflected in significant decreases in mean
MADRS and YMRS scores for subjects at LOCF end
point and for completers (Table 3). Remission was
attained by 53.3% of subjects at LOCF end point and by
61.3% of completers (Figure 2). A 10-point improvement
in GAF score was observed in 62.3% of subjects at
LOCF end point and in 68.9% of completers, with mean
(standard deviation [SD]) GAF scores improving 16.3
(17.1; p < .001) points and 19.0 (16.7; p < .001) points,
respectively (Table 3).
Safety
Safety results were similar to those previously reported
[15]. Most (75.3%) subjects experienced ≥1A Ed u r i n g
this 16-week period. The most common AEs, with an
incidence of ≥10%, were tremor (22.8%), muscle rigidity
(15.4%), weight increase (13.6%), and headache (11.1%).
Eight percent of the population discontinued because of
AEs. At baseline, the mean (SD) weight was 74.1 (20.4)
kg. The mean (SD) weight increase from baseline was
2.0 (4.1) kg for subjects at LOCF end point and 2.1
(4.4) kg for completers (p < .001 vs. baseline for both
comparisons).
Subjects with Depressive Symptoms at Baseline
Efficacy
Mean scores significantly improved on the CGI-BP-S by
week 4 and each subsequent time point (Figure 1).
Remission was achieved by 44.6% of subjects at LOCF
end point and by 56.8% of completers (Figure 2). Mean
MADRS scores decreased significantly at each time
point including LOCF end point (Figure 3). A 10-point
improvement in GAF score was observed in 56.4% of
subjects at LOCF end point and in 63.6% of completers,
and the mean (SD) change from baseline in GAF scores
was 13.0 (16.6) (p < .001) and 15.5 (16.4) (p < .001),
respectively (Table 3).
Safety
The proportion of subjects who had ≥1 AE was 69.5%.
The most common AEs, with an incidence of ≥10%,
were tremor (17.0%), headache (13.6%), muscle rigidity
(11.9%), fatigue (11.9%) and somnolence (10.2%). The
proportion of subjects who discontinued because of AEs
was 10.2%. At baseline, the mean (SD) weight was 72.5
(21.2) kg. The mean (SD) weight increase from baseline
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(3.9) kg for completers (p < .001 vs. baseline for both
comparisons).
Subjects with Manic/Mixed Symptoms at Baseline
Efficacy
The overall clinical status of subjects with manic/mixed
symptoms at baseline also significantly improved, as
seen in significant changes on the CGI-BP-S at each
time point, again starting at Week 4, including LOCF
end point (Figure 1). Remission was attained by 58.2%
of subjects at LOCF end point and by 64.0% of comple-
ters (Figure 2). Mean YMRS scores decreased signifi-
cantly at each time point, including LOCF end point
(Figure 4). There was a small but significant improve-
ment in MADRS scores for completers (p < .05). No sig-
nificant improvement was observed in subjects at LOCF
end point (Table 3). A 10-point improvement in GAF
score was observed in 65.9% of subjects at LOCF end
point and in 72.0% of subjects who completed the study,
Table 1 Baseline demographic and clinical characteristics, disposition, and RLAI mean daily dose and dose distribution
(ITT analysis set)
Total
(N = 162)
Baseline
Depressive Symptoms
(n = 59)
Baseline
Manic or Mixed Symptoms
(n = 103)
Baseline demographic and clinical characteristics
Age, years
Mean (SD) 38.6 (11.4) 41.0 (11.5) 37.2 (11.2)
Median (range) 39 (18-70) 41 (22-70) 38 (18-61)
Gender, n (%)
Male 92 (56.8) 28 (47.5) 64 (62.1)
Female 70 (43.2) 31 (52.5) 39 (37.9)
Race, n (%)
Caucasian 51 (31.5) 19 (32.2) 32 (31.1)
Hispanic 3 (1.9) 2 (3.4) 1 (1.0)
Black 18 (11.1) 5 (8.5) 13 (12.6)
Other (Indian) 90 (55.6) 33 (55.9) 57 (55.3)
Bipolar disorder subtype, n(%)
Type I 144 (88.9) 48 (81.4) 96 (93.2)
Type II 18 (11.1) 11 (18.6) 7 (6.8)
Most recent episode, n (%)
Depressed 56 (34.6) 44 (74.6) 12 (11.7)
Manic 79 (48.8) 6 (10.2) 73 (70.9)
Mixed 19 (11.7) 8 (13.6) 11 (10.7)
Hypomanic 8 (4.9) 1 (1.7) 7 (6.8)
Time since most recent episode, weeks, mean (SD) 6.0 (4.6) 6.1 (4.8) 5.9 (4.5)
Disposition
Completed OL phase 120 (74.1) 44 (74.6) 76 (73.8)
Discontinued 42 (25.9) 15 (25.4) 27 (26.2)
Reason for discontinuation
Withdrawal of consent 14 (8.6) 7 (11.9) 7 (6.8)
AEs 13 (8.0) 6 (10.2) 7 (6.8)
Lost to follow-up 10 (6.2) 2 (3.4) 8 (7.8)
Nonadherent 1 (0.6) 0 (0) 1 (1.0)
Other 4 (2.5)
a 0 (0) 4 (3.9)
a
RLAI mean daily dose and dose distribution
Dose, mg, mean (SD) 27.9 (5.6) 26.5 (4.1) 28.6 (6.2)
Dose distribution, n (%)
25 mg 127 (78.4) 52 (88.1) 75 (72.8)
37.5 mg 33 (20.4) 7 (11.9) 26 (25.2)
50 mg 2 (1.2) 0 (0) 2 (1.9)
OL, open-label; RLAI, risperidone long-acting therapy; SD, standard deviation.
aOf these subjects, 3 discontinued because of lack of efficacy and 1 because of pregnancy.
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scores was 18.4 (17.1) and 21.0 (16.7) (p < .001), respec-
tively (Table 3).
Safety
At least 1 AE was observed in 78.6% of subjects experi-
encing manic/mixed symptoms. The most common AEs
with an incidence of ≥10% were tremor (26.2%), muscle
rigidity (17.5%), weight increase (17.5%), and sedation
(11.7%); 6.8% of subjects discontinued because of AEs.
At baseline, the mean (SD) weight was 75.1 (20.0) kg.
The mean (SD) weight increase from baseline was 1.8
(4.3) kg for subjects at LOCF end point and 1.8 (4.6) kg
for completers (p < .01 vs. baseline for both
comparisons).
Discussion
The efficacy and safety of maintenance RLAI as mono-
therapy or adjunctive therapy in subjects with bipolar
disorder have been confirmed in large, controlled stu-
dies [15,16,21]. However, the particular types of patients
with bipolar disorder who might best be considered for
this treatment have not been fully established. Data
from this post hoc analysis suggest that patients with a
history of frequent relapse who experience acute symp-
toms might benefit from the addition of RLAI to their
current treatment regimen of mood stabilizers, antide-
pressants, and/or anxiolytics.
Because the data reported here represent a post hoc
evaluation, these results are specific to the population
studied here and may not be readily generalizable to
the broader population of patients with bipolar disor-
der. A substantial proportion of subjects entered the
relapse-prevention study with significant symptoms,
despite receiving bipolar disorder medications at base-
line. This may support the fact that this frequently-
relapsing population is difficult to manage and has
poor adherence to medication. The addition of adjunc-
tive RLAI was associated with significant improve-
ments in clinical status and symptoms by week 4, as
determined by the CGI-BP-S, YMRS, and MADRS
scales. Remission was achieved in more than one-half
of the total population by the 16-week LOCF end
point and more than 60% had a 10-point improvement
on the GAF scale.
Table 2 Bipolar disorder medications (ITT population)
OL Baseline
Total
(N = 162)
Baseline
Depressive
Symptoms
(n = 59)
Baseline
Manic/Mixed Symptoms
(n = 103)
Number of bipolar medications
a, b
0 17 (10.5) 5 (8.5) 12 (11.7)
1 37 (22.8) 14 (23.7) 23 (22.3)
2 49 (30.3) 16 (27.1) 33 (32.0)
≥3 59 (36.4) 24 (40.7) 35 (34.0)
Mood stabilizers 128 (79.0) 44 (74.6) 84 (81.6)
Antipsychotics 47 (29.0) 17 (28.8) 30 (29.1)
Antidepressants 48 (29.6) 26 (44.1) 22 (21.4)
Anxiolytics 54 (33.3) 20 (33.9) 34 (33.0)
OL Week 16 (Completers)
Total
(N = 120)
Baseline
Depressive
Symptoms
(n = 44)
Baseline
Manic or Mixed Symptoms
(n = 76)
Number of bipolar disorder medications
a, c
0 8 (6.7) 0 (0) 8 (10.5)
1 41 (34.2) 16 (36.4) 25 (32.9)
2 39 (32.5) 17 (38.6) 22 (29.0)
≥3 32 (26.7) 11 (25.0) 21 (27.6)
Mood stabilizers 99 (82.5) 35 (79.6) 64 (84.2)
Antidepressants 51 (42.5) 28 (63.6) 23 (30.3)
Anxiolytics 32 (26.7) 11 (25.0) 21 (27.6)
ITT, intent to treat; OL, open-label.
aA subject taking > 1 medication within a class and subclass was counted once within the class and subclass.
bClasses included mood stabilizers, antidepressants, antipsychotics, and anxiolytics.
cClasses included mood stabilizers, antidepressants, and anxiolytics.
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Figure 1 Mean CGI-BP-S score over time (ITT analysis set). CGI-BP-S, Clinical Global Impressions of Bipolar Disorder-Severity; LOCF, last
observation carried forward.
Table 3 Efficacy measures: baseline and end point values in the open-label stabilization phase (ITT population)
Total
(N = 162)
Baseline
Depressive Symptoms
(n = 59)
Baseline
Manic or Mixed Symptoms
(n = 103)
CGI-BP-S, mean (SD)
Baseline 4.3 (0.8) 4.2 (0.8) 4.3 (0.8)
Change from baseline
Completers
a -2.1 (1.4)
e -1.9 (1.5)
e -2.2 (1.3)
e
LOCF end point
b -1.8 (1.5)
e -1.5 (1.6)
e -2.0 (1.5)
e
MADRS, mean (SD)
Baseline 15.0 (11.6) 25.4 (6.4) 9.0 (9.5)
Change from baseline
Completers
a -7.2 (11.2)
e -15.6 (10.7)
e -2.2 (8.1)
d
LOCF end point
b -6.0 (12.6)
e -14.0 (11.2)
e -1.4 (11.0)
YMRS, mean (SD)
Baseline 18.8 (12.1) 5.8 (4.5) 26.3 (8.2)
Change from baseline
Completers
a -14.2 (12.5)
e -2.3 (5.5)
d -21.2 (9.9)
e
LOCF end point
b -13.2 (13.8)
e -0.9 (8.6) -20.2 (11.1)
e
GAF
≥10-point improvement (%)
e
Completers
a 68.9 63.6 72.0
LOCF end point
c 62.3 56.4 65.9
Baseline, mean (SD) 50.9 (11.4) 52.5 (10.0) 49.9 (12.1)
Change from baseline, mean (SD)
Completers
a 19.0 (16.7)
e 15.5 (16.4)
e 21.0 (16.7)
e
LOCF end point
c 16.3 (17.1)
e 13.0 (16.6)
e 18.4 (17.1)
e
CGI-BP-S, Clinical Global Impressions of Bipolar Disorder-Severity; GAF, Global Assessment of Functioning; ITT, intent to treat; LOCF, last observation carried
forward; MADRS, Montgomery-Åsberg Depression Rating Scale; SD, standard deviation; YMRS, Young Mania Rating Scale.
an = 119, n = 44, and n = 75;
bn = 154, n = 56, and n = 98;
cn = 146, n = 55, and n = 91 for the total, depressive, and manic/mixed populations, respectively.
dp < .05 vs. baseline;
ep < .001 vs. baseline.
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manic and depressive symptoms of bipolar disorder is
important for patient management. For subjects with
manic/mixed symptoms, RLAI treatment resulted in clini-
cal and symptom improvement within 4 weeks of treat-
ment initiation with significant increases in remission
rates and patient functioning. RLAI also was found to be
effective in subjects with depressive symptoms. These
patients are typically difficult to treat and are associated
with poor functioning [22] and a high frequency of depres-
sive episodes has been reported to be predictive of nonad-
herence [11]. In the current study, subjects with
depressive symptoms showed significant clinical and
symptom improvement by week 4 and a majority of sub-
jects achieved remission. Also, more than half of the sub-
jects with depressive and manic/mixed symptoms
achieved a significant improvement in functioning.
Although the analyses were not preplanned to analyze dif-
ferences in efficacy/tolerability between these groups of
subjects, these data may suggest that RLAI may be effec-
tive regardless of depressive or manic/mixed symptoms.
No unexpected safety or tolerability findings were
identified, and AE rates were similar to those found in
the overall study population [15]. This suggested that
t h et o l e r a b i l i t yp r o f i l em a yb ei n d e p e n d e n to fm o o d
state or severity of symptoms. The mean weight of sub-
jects increased by approximately 2 kg, whether mea-
sured at study end point or at completion of all 16
weeks of treatment.
Although they suggest that RLAI is effective in
patients with bipolar disorder who have frequent
relapses, these results must be interpreted with caution.
As a post hoc analysis of an open-label stabilization
phase of a relapse-presentation, this study did not
include a control group. Nonetheless, the efficacy results
observed in this post hoc analysis with RLAI were gen-
erally similar to those of the open-label stabilization
phase of the overall study [15]. Also, subject compliance
with their individual treatment regimens of mood stabi-
lizers, antidepressants, and/or anxiolytics before study
entry was not established. Therefore, improvements
seen in this analysis may be due in part to noncompli-
ance with previous medications. Additionally, due to the
release profile of RLAI (< 1% of risperidone is released
during the first 3 weeks) [23] oral supplementation with
antipsychotics was required for the first 3 weeks of the
study. This may have influenced the results at the earlier
time points. However, by the week 4 assessment the
  Depressive: n = 59           54            48            46            44                             56         
Manic/Mixed: n = 103         97            87            80            75                             98 
            Total: n = 162        151          135           126         119                            154 
S
u
b
j
e
c
t
s
 
(
%
)
 
Time (weeks) 
48 1 2 1 6
0
20
40
60
80
100
Baseline LOCF 
end point
Total Population
Manic/Mixed
Depressive
Figure 2 Point remission rates. LOCF, last observation carried forward (ITT analysis set).
Macfadden et al. BMC Psychiatry 2011, 11:171
http://www.biomedcentral.com/1471-244X/11/171
Page 7 of 10n = 59                54                    48                 46                  44                                      56 
M
e
a
n
 
M
A
D
R
S
 
 
S
c
o
r
e
 
a 
a 
a  a 
a 
SD = 6.4 
SD = 9.8 
SD = 8.9 
SD = 10.2 
SD = 11.0
 
SD = 10.7 
ap <.0001, change from baseline. 
Time (weeks) 
28
24
20
16
4 8 12 16
12
8
4
Baseline LOCF 
end point
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scribing information [23]. Remission was analyzed at
each individual time point and did not account for a
subject’s remission status at previous time points during
the open-label stabilization phase. Therefore, the per-
centage of subjects who met stable remission criteria
could not be established. Nonetheless, over half of sub-
jects met remission criteria by week 16. Although there
may appear to be differences in onset of remission for
the 2 subpopulations there were substantial between-
group differences in baseline demographics, baseline dis-
ease characteristics, symptomatology, as well as the
scales used to measure symptoms. While these data may
be hypothesis-generating, the timing of improvement of
symptom domains among these different subpopulations
could not be established.
Conclusions
To summarize, in subjects with symptomatic bipolar
disorder who experienced frequent relapses, significant
improvements were observed with regard to mood
symptoms, clinical status, and functioning, after the
addition of RLAI to their current treatment regimen of
mood stabilizers, antidepressants, and/or anxiolytics.
Remission was achieved by approximately one-half of all
subjects during 16 weeks of treatment, with improve-
ment observed as early as 4 weeks. Benefits were
observed in subjects with depressive symptoms or
manic/mixed symptoms. The addition of RLAI, there-
fore, may be useful for adjunctive treatment in patients
with bipolar disorder who continue to frequently experi-
ence symptoms despite previous and ongoing treatment.
Acknowledgements
This study was supported by funding from Janssen Scientific Affairs, LLC.
Study Institutional Review Boards and Ethics Committees
USA
Coast IRB, LLC, San Clemente, California; Institutional Review Board - Medical
Center, Cincinnati, Ohio; Western Institutional Review Board, Olympia,
Washington; Sharp HealthCare, San Diego, California; UCI Institutional Review
Board, Irvine, California; McLean Hospital Cognitive Neuroimaging
Laboratory, Belmont, Massachusetts
India
SMS Medical College, Jaipur; KS Hegde Medical Academy, Deralkatte,
Mangalore (D.K.); Asha Hospital, Institute of Medical Psychology Counselling
& Psychotherapy, Banjara Hills, Hyderabad; National Institute of Mental
Health and Neurosciences, Bangalore; Madras Medical College &
Government General Hospital, Chennai; Kasturba Hospital Manipal, Karnataka;
King George’s Medical University, Lucknow; Dr. R.N. Cooper Municipal
General Hospital, Mumbai; Government Medical College & Chest Hospital,
Mulankunnathukavu, Thrissur Kerala; St. John’s Medical College Hospital,
Bangalore; G.B. Pant Hospital, New Delhi; Post Graduate Institute of Medical
Education and Research, Chandigarh; B.J. Medical College and Civil Hospital,
Ahmedabad; Lokmanya Tilak Municipal Medical College and Lokmanya Tilak
Municipal General Hospital, Sion, Mumbai, Maharashtra; Sri Venkateswara
Medical College, Tirupati; Madras Medical College & Research Institute,
Kilpauk, Chennai; VIMHANS Hospital, New Delhi; K.S. Hegde Medical
Academy, Mangalore (D.K.).
The authors wish to acknowledge the contributions of Cynthia A. Bossie
(employee of Janssen Scientific Affairs, LLC, Titusville, NJ, USA) in the
development of this manuscript.
The authors also wish to acknowledge Matthew Grzywacz, PhD, Mariana
Ovnic, PhD, and ApotheCom (funding supported by Janssen Scientific
Affairs, LLC, Titusville, NJ) in the development and submission of this article.
Author details
1Formerly, Janssen Scientific Affairs, LLC, Titusville, NJ, USA.
2University of
Cincinnati College of Medicine, Cincinnati, OH, USA.
3Johnson & Johnson
Pharmaceutical Research and Development, LLC, Titusville, NJ, USA.
4Janssen
Scientific Affairs, LLC, Titusville, NJ, USA.
Authors’ contributions
WM, LA, IT, JTH, and NT contributed to the conception and design,
acquisition of data, analysis and interpretation of data, and drafting of the
manuscript and its critical revision for important intellectual content. CMA
was involved in the interpretation of data and in the critical drafting and
revising of the manuscript for important intellectual content. All authors
read and approved the final manuscript.
Competing interests
At the time of this analysis, W Macfadden was a full-time employee of
Janssen Scientific Affairs, LLC. L Alphs and N Turner are full-time employees
of Janssen Scientific Affairs, LLC, and Johnson & Johnson stockholders. JT
Haskins and I Turkoz are full-time employees of Johnson & Johnson
Pharmaceutical Research and Development, LLC, and Johnson & Johnson
stockholders. CM Adler over the last 12 months has received honoraria for
speaking and consulting from Merck, as well as research support from
Abbott Laboratories, AstraZeneca, Eli Lilly, Shire, Johnson & Johnson, Pfizer,
Repligen, and Martek. With the exception of AstraZeneca, the research
support has been in the form of payments for multisite clinical trials.
Received: 20 December 2010 Accepted: 28 October 2011
Published: 28 October 2011
References
1. Keck PE Jr, McElroy SL, Strakowski SM, West SA, Sax KW, Hawkins JM,
Bourne ML, Haggard P: 12-month outcome of patients with bipolar
disorder following hospitalization for a manic or mixed episode. Am J
Psychiatry 1998, 155:646-652.
2. Judd LL, Akiskal HS: The prevalence and disability of bipolar spectrum
disorders in the US population: re-analysis of the ECA database taking
into account subthreshold cases. J Affect Discord 2003, 73:123-131.
3. Bowden CL: Bipolar disorder and work loss. Am J Manag Care 2005, 11:
S91-S94.
4. Kessler RC, Akiskal HS, Ames M, Birnbaum H, Greenberg P, Hirschfeld RM,
Jin R, Merikangas KR, Simon GE, Wang PS: Prevalence and effects of mood
disorders on work performance in a nationally representative sample of
U.S. workers. Am J Psychiatry 2006, 163:1561-1568.
5. Laxman KE, Lovibond KS, Hassan MK: Impact of bipolar disorder in
employed populations. Am J Manag Care 2008, 14:757-764.
6. Hirschfeld RMA, Bowden CL, Gitlin MJ, Keck PE, Suppes T, Thase ME,
Wagner KD, Perlis RH: Practice Guideline for the Treatment of Patients
With Bipolar Disorder., Second 2002, 1-82.
7. Coryell W: Rapid cycling bipolar disorder: clinical characteristics and
treatment options. CNS Drugs 2005, 19:557-569.
8. Baldessarini RJ, Tondo L, Floris G, Hennen J: Effects of rapid cycling on
response to lithium maintenance treatment in 360 bipolar I and II
disorder patients. J Affect Discord 2000, 61:13-22.
9. Perlis RH, Ostacher MJ, Miklowitz DJ, Hay A, Nierenberg AA, Thase ME,
Sachs GS: Clinical features associated with poor pharmacologic
adherence in bipolar disorder: results from the STEP-BD study. J Clin
Psychiatry 2010, 71:296-303.
10. Martinez-Aran A, Scott J, Colom F, Torrent C, Tabares-Seisdedos R, Daban C,
Leboyer M, Henry C, Goodwin GM, Gonzalez-Pinto A, Cruz N, Sanchez-
Moreno J, Vieta E: Treatment nonadherence and neurocognitive
impairment in bipolar disorder. J Clin Psychiatry 2009, 70:1017-1023.
11. Gutierrez-Rojas L, Jurado D, Martinez-Ortega JM, Gurpegui M: Poor
adherence to treatment associated with a high recurrence in a bipolar
disorder outpatient sample. J Affect Discord 2010, 127:77-83.
Macfadden et al. BMC Psychiatry 2011, 11:171
http://www.biomedcentral.com/1471-244X/11/171
Page 9 of 1012. Hassan M, Lage MJ: Risk of rehospitalization among bipolar disorder
patients who are nonadherent to antipsychotic therapy after hospital
discharge. Am J Health-Syst Pharm 2009, 66:358-365.
13. Kane JM: Dosing issues and depot medication in the maintenance
treatment of schizophrenia. Int Clin Psychopharmacol 1995, 10:65-71.
14. Vieta E, Nieto E, Autet A, Rosa AR, Goikolea JM, Cruz N, Bonet P: A long-
term prospective study on the outcome of bipolar patients treated with
long-acting injectable risperidone. World J Biol Psychiatry 2008, 9:219-224.
15. Macfadden W, Alphs L, Haskins JT, Turner N, Turkoz I, Bossie C, Kujawa M,
Mahmoud R: A randomized, double-blind, placebo-controlled study of
maintenance treatment with adjunctive risperidone long-acting therapy
in patients with bipolar I disorder who relapse frequently. Bipolar Dis
2009, 11:827-839.
16. Quiroz JA, Yatham LN, Palumbo JM, Karcher K, Kushner S, Kusumakar V:
Risperidone long-acting injectable monotherapy in the maintenance
treatment of bipolar I disorder. Biol Psychiatry 2010, 68:156-162.
17. Montgomery SA, Asberg M: A new depression scale designed to be
sensitive to change. Br J Psychiatry 1979, 134:382-389.
18. Young RC, Biggs JT, Ziegler VE, Meyer DA: A rating scale for mania:
reliability, validity and sensitivity. Br J Psychiatry 1978, 133:429-435.
19. Spearing MK, Post RM, Leverich GS, Brandt D, Nolen W: Modification of the
Clinical Global Impressions (CGI) scale for use in bipolar illness (BP): the
CGI-BP. Psychiatry Res 1997, 73:159-171.
20. Jones SH, Thornicroft G, Coffey M, Dunn G: A brief mental health outcome
scale-reliability and validity of the Global Assessment of Functioning
(GAF). Br J Psychiatry 1995, 166:654-659.
21. Montgomery S, Vieta E, Sulaiman AH, Cordoba R, Huberlant B, Schreiner A,
Martinez G: Randomized, double-blind, placebo-controlled study of
risperidone long-acting injectable in relapse prevention in patients with
bipolar I disorder. Presented at the European Psychiatric Association 18th
European Congress of Psychiatry, Munich, Germany 2010.
22. Rosa AR, Reinares M, Michalak EE, Bonnin CM, Sole B, Franco C, Comes M,
Torrent C, Kapczinski F, Vieta E: Functional impairment and disability
across mood states in bipolar disorder. Value Health 2010.
23. Riperdal
® Consta
® [prescribing information]. Titusville, NJ: Ortho-McNeil
Janssen; 2010.
Pre-publication history
The pre-publication history for this paper can be accessed here:
http://www.biomedcentral.com/1471-244X/11/171/prepub
doi:10.1186/1471-244X-11-171
Cite this article as: Macfadden et al.: Adjunctive long-acting risperidone
in patients with bipolar disorder who relapse frequently and have
active mood symptoms. BMC Psychiatry 2011 11:171.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Macfadden et al. BMC Psychiatry 2011, 11:171
http://www.biomedcentral.com/1471-244X/11/171
Page 10 of 10